Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Rapid Therapeutic Science Laboratories Liabilities-to-Assets Related Terms
Rapid Therapeutic Science Laboratories Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTSL vs VRAYQ, NNMX, ABT: Liabilities-to-Assets Comparison
For the Shell Companies subindustry, Rapid Therapeutic Science Laboratories's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Therapeutic Science Laboratories Liabilities-to-Assets vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Rapid Therapeutic Science Laboratories's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Rapid Therapeutic Science Laboratories's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories (RTSL) has a Liabilities-to-Assets of 2.32 as of Jun. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rapid Therapeutic Science Laboratories and its competitors.
Is Rapid Therapeutic Science Laboratories' Liabilities-to-Assets too high?
Rapid Therapeutic Science Laboratories' current Liabilities-to-Assets is 2.32.
How does Rapid Therapeutic Science Laboratories' Liabilities-to-Assets compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' Liabilities-to-Assets of 2.32 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Diversified Financial Services company?
A good Liabilities-to-Assets depends on the Diversified Financial Services industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rapid Therapeutic Science Laboratories and its competitors. Rapid Therapeutic Science Laboratories's current Liabilities-to-Assets is 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current Liabilities-to-Assets of 2.32. The current Liabilities-to-Assets is 2.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current Liabilities-to-Assets is 2.32 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RTSL has been successfully added to your 
